TNXP Stock — Tonix Pharmaceuticals Holding Corp.: Cash, EV, Pipeline

Share price

$10.87

Market cap

$186.4M

Cash

$176.2M

Enterprise value

$18.9M

Balance sheet

Cash	$176.2M
Debt	$8.7M
Net cash	$167.5M
Enterprise value	$18.9M
Basic shares	16.8M shares
Fully diluted shares	19.5M shares
Fully diluted market cap	$211.5M
Cash per share	$10.49

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading TNXP daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 14 - Apr 25	TNX-102 SL	Phase 2	Major Depressive Episode (MDE); Major Depressive Disorder (MDD); Depression	—
Oct 13 - Nov 24	TNX-1500	Phase 2	Kidney Transplant; Kidney Transplant Failure and Rejection; Immunosuppression	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

TONMYA

Approved · Active Modality: small molecule

Aliases TNX-102 SL, cyclobenzaprine HCl sublingual tablets

Partnerships U.S. Department of Defense (OASIS study grant, UNC investigator-initiated IND)

Indications

Fibromyalgia (Approved)
Major depressive disorder (Phase 2)
Acute stress disorder / acute stress reaction (Phase 2)

Catalysts

— mid-2027

Status note FDA-approved, first new medicine for fibromyalgia in 15+ years. Potentially pivotal Phase 2 HORIZON study as first-line monotherapy in MDD; OASIS study for ASD/ASR funded by DoD grant.

TNX-4800

Phase 2 · Active Modality: antibody

Aliases mAb 2217LS

Target Borrelia OspA

Partnerships UMass Chan Medical School (license)

Indications

Lyme disease prevention (Phase 2)

Catalysts

— first quarter of 2027

Status note Anti-Borrelia OspA human monoclonal antibody; Type C FDA meeting minutes support adaptive Phase 2 field study initiation.

TNX-1500

Phase 2 · Active Modality: antibody

Target CD40L (CD154)

Partnerships Massachusetts General Hospital (investigator-initiated Phase 2)

Indications

Kidney transplant rejection (Phase 2)
Autoimmune diseases (Phase 2)

Status note Fc-modified humanized anti-CD40L (CD154) monoclonal antibody; Phase 2-ready for prevention of kidney transplant rejection and treatment of autoimmune diseases.

TNX-1300

Phase 2 · Active Modality: enzyme

Aliases double-mutant cocaine esterase

Target cocaine

Partnerships NIH/NIDA (grant support)

Indications

Cocaine intoxication (Phase 2)

Status note FDA Breakthrough Therapy designation; Phase 2a in clinical development for cocaine intoxication.

Per-asset detail extracted from the 10-Q filed 2026-08-10. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	TNX-102 SL
Lead indication	Major Depressive Episode (MDE)
Lead phase	Phase 2
Active trials	2
Collaborator trials	4

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07621237	Phase 2	Recruiting	Sponsor	Tonix Pharmaceuticals, Inc.	—	Major Depressive Episode (MDE); Major Depressive Disorder (MDD); Depression	—
NCT07413367	Phase 1	Active, not recruiting	Sponsor	Tonix Pharmaceuticals, Inc.	—	Pharmakokinetic; Open Label; Phase 1	—
NCT07730294	Phase 2	Not yet recruiting	Collaborator	Yale University	—	Pain; Pituitary Surgery	—
NCT07204080	Phase 2	Not yet recruiting	Collaborator	Ayman Al Jurdi, MD	—	Kidney Transplant; Kidney Transplant Failure and Rejection; Immunosuppression	—
NCT06636786	Phase 2	Recruiting	Collaborator	University of North Carolina, Chapel Hill	—	Acute Stress Reaction; Acute Stress Disorder; Neurocognitive Function	—
NCT04789148	Phase 1	Recruiting	Collaborator	Elizabeth Austen Lawson	—	Vasopressin Deficiency	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 4 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 6 active trials for Tonix Pharmaceuticals, Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

TNXP — Tonix Pharmaceuticals Holding Corp.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials